cupure logo
trumptariffsseasonhit2025costshometrumpsbanneddeal

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company announces cost cuts after fierce competition and Trump tariff threat hit growthSales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus.The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe’s most valuable company, has lost $95bn (£71.5bn) in market value since cutting its full-year sales forecast last week. Continue reading...

Comments

Similar News

Business News